Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

I’m one of the first Americans to be cured of type 1 diabetes thanks to a breakthrough therapy

Key Takeaway: A recent article highlights the success of a breakthrough therapy that has cured type 1 diabetes in some patients. This innovative treatment is transforming lives and represents a significant advancement in diabetes care. The therapy has garnered attention for its potential to change the future of diabetes management.
Price reaction · baseline $2.62 (2024-10-04 close) · 1 other ELDN headline(s) in the window, move may be shared
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Breakthrough therapy has cured type 1 diabetes in patients.
  • The therapy represents a significant advancement in diabetes treatment.
  • Patient stories highlight transformative experiences.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is the breakthrough therapy for type 1 diabetes?

The breakthrough therapy is a new treatment that has successfully cured type 1 diabetes in some patients.

How does the therapy transform lives?

The therapy transforms lives by effectively managing and curing type 1 diabetes, allowing patients to lead healthier lives.

What impact does this therapy have on diabetes care?

This therapy represents a significant advancement in diabetes care, potentially changing treatment approaches.

Are there patient stories available?

Yes, the article includes patient stories that highlight their transformative experiences with the therapy.

Last updated: Oct 6, 2024